Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter Open-label Phase 1/1b Study to Evaluate the Safety and Preliminary Efficacy of SO-C101 as Monotherapy and in Combination With Pembrolizumab in Patients With Selected Advanced/Metastatic Solid Tumors

Next Previous
X
Search
Trial Profile

A Multicenter Open-label Phase 1/1b Study to Evaluate the Safety and Preliminary Efficacy of SO-C101 as Monotherapy and in Combination With Pembrolizumab in Patients With Selected Advanced/Metastatic Solid Tumors

Status: Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 27 Sep 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Nanrilkefusp alfa (Primary) ; Pembrolizumab (Primary)
  • Indications Advanced breast cancer; Anal cancer; Biliary cancer; Bladder cancer; Carcinoma; Cervical cancer; Colorectal cancer; Gastric cancer; Head and neck cancer; Liver cancer; Malignant melanoma; Malignant thymoma; Merkel cell carcinoma; Mesothelioma; Non-small cell lung cancer; Ovarian cancer; Renal cell carcinoma; Skin cancer; Small cell lung cancer; Solid tumours; Squamous cell cancer; Thyroid cancer
  • Focus Adverse reactions; First in man
  • Acronyms AURELIO-03
  • Sponsors SOTIO

    • Most Recent Events

    • 19 Sep 2024 Planned End Date changed from 1 Nov 2024 to 1 Dec 2024.
    • 19 Sep 2024 Planned primary completion date changed from 1 Aug 2024 to 1 Dec 2024.
    • 06 Mar 2024 Planned End Date changed from 1 Dec 2023 to 1 Nov 2024.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top